Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

(2012) A. Tefferi   BLOOD

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

(2012) M. Gupta et al.   BLOOD

Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells

(2012) L. Zhang et al.   BLOOD

Janus Kinase Deregulation in Leukemia and Lymphoma

(2012) Edwin Chen et al.   IMMUNITY

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

(2012) Hanna L.M. Koskela et al.   NEW ENGLAND JOURNAL OF MEDICINE

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

(2012) V Novotny-Diermayr et al.   Blood Cancer Journal

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

(2012) Ghee Chong Koo et al.   Cancer Discovery

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

(2011) K. Van Roosbroeck et al.   BLOOD

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

(2011) N. E. Elliott et al.   BLOOD

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

(2011) A. Scuto et al.   CANCER RESEARCH

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma

(2011) M. Kleppe et al.   HAEMATOLOGICA

The Transcription Factor STAT3 Is Required for T Helper 2 Cell Development

(2011) Gretta L. Stritesky et al.   IMMUNITY

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

(2011) Wu ZL et al.   Journal of Hematology & Oncology

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

(2011) Anthony D. William et al.   JOURNAL OF MEDICINAL CHEMISTRY

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

(2011) A V Purandare et al.   LEUKEMIA

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis

(2011) Tania Diaz et al.   PLoS One

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

(2011) Y Nakaya et al.   Blood Cancer Journal

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma

(2011) E Derenzini et al.   Blood Cancer Journal

PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells

(2010) W. Koestner et al.   BLOOD

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells

(2010) B. Will et al.   BLOOD

STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction

(2010) H. Nguyen-Jackson et al.   BLOOD

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

STAT3 controls myeloid progenitor growth during emergency granulopoiesis

(2010) H. Zhang et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

JAK2 inhibitors: What's the true therapeutic potential?

(2010) Fabio P.S. Santos et al.   BLOOD REVIEWS

Cooperative Epigenetic Modulation by Cancer Amplicon Genes

(2010) Lixin Rui et al.   CANCER CELL

Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis

(2010) Lydia Durant et al.   IMMUNITY

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape

(2010) Donatella Aldinucci et al.   JOURNAL OF PATHOLOGY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival

(2010) T. W. Hand et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma

(2009) O. Ritz et al.   BLOOD

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models

(2009) M. G. Cornejo et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities

(2009) A. Mottok et al.   BLOOD

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

(2009) Y. Wang et al.   BLOOD

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma

(2008) Maurizio Martini et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Cytokine Signaling Modules in Inflammatory Responses

(2008) John J. O'Shea et al.   IMMUNITY

PIASy Represses CCAAT/Enhancer-binding Protein δ (C/EBPδ) Transcriptional Activity by Sequestering C/EBPδ to the Nuclear Periphery

(2008) Shanggen Zhou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Priming for T helper type 2 differentiation by interleukin 2–mediated induction of interleukin 4 receptor α-chain expression

(2008) Wei Liao et al.   NATURE IMMUNOLOGY

The exploration of macrocycles for drug discovery — an underexploited structural class

(2008) Edward M. Driggers et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD